Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is trading up 93.59% versus 12-month low of 7.65 and stands -24.52% lower from its 1-year peak of $19.62. The consensus price target (PT) of $24.67 means that the market expects Company shares to increase by 69.3% in the short run. The sell-side target prices range from $18 to $33. In the last month the stock has moved in price -4.39%, with a one year change of 38.80%. The last trading session volume compares with the 660.62K average and market worth floats around 1.54B.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) gained 1.65% to reach at the trading price of $14.81 as it is set to release its next quarterly earnings report on February 22, 2017. Lexicon Pharmaceuticals, Inc. stock trades in the range of $14.15 to $14.84 before the earnings release. Let’s take a closer look at the current earnings forecast, particularly the things traders should pay close attention to. Earnings per share for the recently concluded quarter is expected to come in at $-0.52 a share with $15.64M in revenue.
Lexicon Pharmaceuticals, Inc. (LXRX) Future Earnings & History
After upcoming fiscal quarter results, all eyes will be on the prospects for the next reporting quarter. Analysts, on average, forecast Lexicon Pharmaceuticals, Inc. to earn $-0.54 per share (EPS) on revenue of $4.4M. The EPS consensus range is $-0.62-$-0.43 on revenue between $4.4M and $4.4M.
While if we look at the Earnings Track Record, Lexicon Pharmaceuticals, Inc. (LXRX) managed to surpass quarterly earnings per share estimates in 7 of the trailing twelve fiscal quarters, and has a positive trend with an average surprise of 58%. Last time the company reported, Lexicon Pharmaceuticals, Inc. (LXRX) generated $-0.35 in earnings per share, beating the consensus estimate of $-0.49. Revenues hit $27.72M in the September 2017 quarter, which was below the consensus $9.68M projection. On the other hand, in the June 2017 quarter the company recorded a net $20.09M revenue with earnings per share of $-0.37. Wall Street had anticipated $12.36M and $-0.40, respectively. For comparison, there was a revenue of $12.49M and EPS of $-0.34 in the March 2016 period.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Analyst Insights
The buoyancy in the outlook of Lexicon Pharmaceuticals, Inc. (LXRX) is getting stronger by the somewhat negative sentiment (2.00 on a 5-point scale) that sell-side analysts have provided concerning it. Brokerage firms on the average advocate the company shares as Buy. Citigroup has been covering shares of LXRX, so it is most recent view is worth a look. In a research note issued on Sep 28, 2015, analysts at Gabelli& Co lifted the stock to Hold from Sell. Another noteworthy analyst activity was recorded on Sep 18, 2015. Downgraded the stock to Sell from Hold.